How do we manage cardiopulmonary bypass coagulopathy?
- 18 June 2014
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 54 (9) , 2158-2166
Abstract
Background: Patients who undergo cardiopulmonary bypass (CPB) are at risk for coagulopathy. Suboptimal turnaround time (TAT) of laboratory coagulation testing results in empiric administration of blood products to treat massive bleeding. We describe our initiative in establishing the coagulation‐based hemotherapy (CBH) service, a clinical pathology consultation service that uses rapid TAT coagulation testing and provides comprehensive assessment of bleeding in patients undergoing CPB. A transfusion algorithm that treats the underlying cause of coagulopathy was developed.Study Design and Methods: The coagulation testing menu includes all aspects of coagulopathy with close proximity of the laboratory to the operating room to allow for rapid test results. The hemotherapy pathologist monitors laboratory results at several stages in surgery and uses a comprehensive algorithm to monitor a patient's hemostasis. The optimal number and type of blood products are selected when the patient is taken off CPB.Results: The CBH service was consulted for 44 ventricular assist device implants, 30 heart transplants, and 31 other cardiovascular surgeries from May 2012 through November 2013. The TAT for laboratory tests was 15 minutes for complete blood count, antithrombin, and coagulation panel and 30 minutes for VerifyNow and thromboelastography, in comparison to 45 to 60 minutes in normal settings. The transfusion algorithms were used with optimal administration of blood components with preliminary data suggestive of reduced blood product usage and better patient outcomes.Conclusion: We described the successful introduction of a novel pathology consultation service that uses a rapid TAT coagulation testing menu with transfusion algorithms for improved management of CPB patients.Keywords
This publication has 26 references indexed in Scilit:
- Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human BloodPLOS ONE, 2013
- The transfusion medicine specialist as a coagulation consultant: a new variant of therapeutic pathologyTransfusion, 2012
- How I treat anticoagulated patients undergoing an elective procedure or surgeryBlood, 2012
- Dabigatran EtexilateCirculation, 2011
- Model for End-Stage Liver Disease Score Predicts Left Ventricular Assist Device Operative Transfusion Requirements, Morbidity, and MortalityCirculation, 2010
- Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist DeviceNew England Journal of Medicine, 2009
- Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agentsBlood, 2008
- Principles of cardiopulmonary bypassContinuing Education in Anaesthesia Critical Care & Pain, 2006
- Clinical Pathology Consultation Improves Coagulation Factor Utilization in Hospitalized AdultsAmerican Journal of Clinical Pathology, 2003
- Fibrinolysis during cardiac surgeryRelease of tissue plasminogen activator in arterial and coronary sinus bloodEuropean Journal of Cardio-Thoracic Surgery, 1994